31.56
+0.15(+0.48%)
Currency In USD
Address
301 Binney Street
Cambridge, MA 02142
United States of America
Phone
857 259 3860
Website
Sector
Healthcare
Industry
Biotechnology
Employees
128
First IPO Date
May 25, 2018
| Name | Title | Pay | Year Born |
| Mr. David L. Hallal | Chief Executive Officer & Chairman of the Board | 175,732 | 1966 |
| Dr. Akshay K. Vaishnaw M.D., Ph.D. | President of R&D, Member of Scientific Advisory Board and Director | 56,140 | 1963 |
| Ms. Junlin Ho J.D. | General Counsel & Corporate Secretary | 563,729 | 1979 |
| Mr. Mo Qatanani Ph.D. | Chief Scientific Officer | 704,681 | 1974 |
| Dr. Jing L. Marantz M.B.A., M.D., Ph.D. | Chief Medical Officer | 755,185 | 1965 |
| Ms. Erin Moore CPA | Interim Principal Financial & Accounting Officer | 0 | 1975 |
| Mr. Robert Keith Woods | Chief Operating Officer | 0 | 1968 |
| Mr. Vikas Sinha C.A., CPA, M.B.A. | Chief Financial Officer | 0 | 1963 |
| Ms. Caryn Parlavecchio | Chief Human Resources Officer | 0 | 1972 |
| Ms. Rushmie Nofsinger | Vice President of Corporate Affairs & Investor Relations | 0 | N/A |
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
